Advertisement

Journal of Cancer Research and Clinical Oncology

, Volume 139, Issue 2, pp 187–194 | Cite as

Prognostic value of ERCC1 in head and neck carcinoma treated with definitive or adjuvant radiotherapy

  • Vesna BišofEmail author
  • Antonija Jakovčević
  • Sven Seiwerth
  • Zoran Rakušić
  • Slavko Gašparov
Original Paper

Abstract

Purpose

To evaluate the prognostic significance of excision repair cross-complementation group 1 (ERCC1) expression in head and neck carcinoma patients treated with definitive radiotherapy (DR) or adjuvant radiotherapy (AR).

Methods

ERCC1 expression was assessed by immunohistochemical staining. A total of 48 patients were assessed.

Results

High ERCC1 expression was found in 23 patients (48 %). More ERCC1-positive tumours were detected in patients treated with DR than in patients treated with AR (73 vs. 36 %, respectively, p = 0.03). ERCC1 expression had no impact on overall survival neither in the whole cohort of patients (p = 0.16) nor in each particular treatment group (AR p = 0.98; DR p = 0.21).

Conclusions

ERCC1 expression had no predictive value in head and neck carcinoma patients treated with DR or AR. There might be difference in ERCC1 positivity that comes out of whether the assessment is done on biopsy or surgical specimens.

Keywords

Head and neck carcinoma Radiotherapy Prognostic value ERCC1 

Notes

Conflict of interest

We declare that we have no conflict of interest.

References

  1. Ahmad A, Robinson AR, Duensing A, van Drunen E, Berna Beverloo H, Weisberg H, Hasty P, Hoeijmakers JHJ, Niedernhofer LJ (2008) ERCC1-XPF endonuclease facilitates DNA double-strand break repair. Mol Cell Biol 28:5082–5092PubMedCrossRefGoogle Scholar
  2. Bergstralh DT, Sekelsky J (2008) Interstrand crosslink repair: can XPF-ERCC1 be let off the hook? Trends Genet 24:70–76PubMedCrossRefGoogle Scholar
  3. Carles J, Monzo M, Amat M, Jansa S, Artells R, Navarro A, Foro P, Alameda F, Gayete A, Gel B, Miguel M, Albanell J, Fabregat X (2006) Single-nucleotide polymorphisms in base excision repair, nucleotide excision repair, and double strand break genes as markers for response to radiotherapy in patients with stage I to II head and neck cancer. Int J Radiat Oncol Biol Phys 66:1022–1030PubMedCrossRefGoogle Scholar
  4. De Castro G, Jr Pasini FS, Siqueira SA, Ferraz AR, Villar RC, Snitcovsky IM, Federico MH (2011) ERCC1 protein, mRNA expression and T19007C polymorphism as prognostic markers in head and neck squamous cell carcinoma patients treated with surgery and adjuvant cisplatin-based chemoradiation. Oncol Rep 25:693–699PubMedGoogle Scholar
  5. De Silva IU, McHugh PJ, Clingen PH, Hartley JA (2000) Defining the roles of nucleotide excision repair and recombination in the repair of DNA interstrand cross-links in mammalian cells. Mol Cell Biol 20:7980–7990PubMedCrossRefGoogle Scholar
  6. Doll CM, Prystajecky M, Eliasziw M, Klimowicz AC, Petrillo SK, Craighead PS, Hao D, Diaz R, Lees-Miller SP, Magliocco AM (2010) Low ERCC1 and protein expression are associated with worse survival in cervical cancer patients treated with radiation alone. Radiother Oncol 97:352–359PubMedCrossRefGoogle Scholar
  7. Ferrigan L, Wallace WA (2004) Predicting non-small cell lung cancer expression of epidermal growth receptor and matrix metalloproteinase 9 from immunohistochemical staining of diagnostic biopsy samples. Eur J Cancer 40:1589–1592PubMedCrossRefGoogle Scholar
  8. Fountzilas G, Kalogera-Fountzila A, Lambaki S, Wirtz RM, Nikolau A, Karayannopoullou G, Bobos M, Kotoula V, Murray S, Lambropoulos A, Aravantinos G, Markou K, Athanassiou E, Misailidou D, Kalogeras KT, Skarlos D (2009) MMP9 but not EGFR, MET, ERCC1, P16 and P-53 is associated with response to concomitant radiotherapy, Cetuximab and weekly cisplatin in patients with locally advanced head and neck cancer. J Oncol. doi: 10.1155/2009/305908
  9. Goyal S, Parikh RR (2010) Clinicopathologic significance of excision repair cross-complementation 1 expression in patients treated with breast-conserving surgery and radiation therapy. Int J Radiat Oncol Biol Phys 76:679–684PubMedCrossRefGoogle Scholar
  10. Gregoire V, Lefebvre J-L, Licitra L, Felip E (2010) Squamous cell carcinoma of the head and neck: EHNS-ESMO-ESTRO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 21(suppl. 5):v184–v186PubMedCrossRefGoogle Scholar
  11. Guo WF, Lin RX, Huang J, Zhou Z, Yang J, Guo GZ, Wang SQ (2005) Identification of differentially expressed genes contributing to radioresistance in lung cancer cells using microarray analysis. Radiat Res 164:27–35PubMedCrossRefGoogle Scholar
  12. Hayes M, Lan C, Yan J, Xie Y, Gray T, Amirkhan RH, Dowell JE (2011) ERCC1 expression and outcomes in head and neck cancer treated with concurrent cisplatin and radiation. Anticancer Res 31:4135–4139PubMedGoogle Scholar
  13. Hwang IG, Ahn MJ, Park BB, Ahn YC, Han J, Lee S, Kim J, Shim YM, Ahn JS, Park K (2008) ERCC1 expression as a prognostic marker in N2 (+) nonsmall-cell lung cancer patients treated with platinum-based neoadjuvant concurrent chemoradiotherapy. Cancer 113:1379–1386PubMedCrossRefGoogle Scholar
  14. Jeong J, Hong S-J, Ju Y-J, Kim B-Y, Park M-J, Kim T-H, Park C-I, Choi K-Y, Cho M-H, Kim S-H, Lee H, Lee K-H (2006) Temporal cDNa microarray analysis of gene expression in human hepatocellular carcinoma upon radiation exposure. Oncol Rep 15:33–48PubMedGoogle Scholar
  15. Johung KL, Rewari A, Wu H, Contessa J, Haffty B, Decker R (2010) Role of excision repair cross complementation 1 expression as a prognostic marker for response to radiotherapy in early stage laryngeal cancer. Proceeding of the 52nd annual ASTRo meeting. Int J Radiat Oncol Biol Phys 78(Suppl):abstr. 3000Google Scholar
  16. Jun HJ, Ahn MJ, Kim HS, Yi SY, Han J, Lee SK, Ahn YC, Jeong H-S, Son Y-I, Baek J-H, Park K (2008) ERCC1 expression as a predictive marker of squamous cell carcinoma of the head and neck treated with cisplatin-based concurrent chemoradiation. Br J Cancer 99:167–172PubMedCrossRefGoogle Scholar
  17. Kamangar F, Dores GM, Anderson WF (2006) Patterns of cancer incidence, mortality and prevalence across five continents. Defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 24:2137–2150PubMedCrossRefGoogle Scholar
  18. Kim MK, Cho K-J, Kwon GY, Park S-I, Kim YH, Kim JH, Song H-Y, Shin JH, Jung HY, Lee GH, Choi KD, Kim S-B (2008) Patients with ERCC1 negative locally advanced esophageal cancers may benefit from preoperative chemoradiotherapy. Clin Cancer Res 14:4225–4231PubMedCrossRefGoogle Scholar
  19. Kirschner K, Melton DW (2010) Multiple roles of the ERCC1-XPF endonuclease in DNA repair and resistance to anticancer drugs. Anticancer Res 30:3223–3232PubMedGoogle Scholar
  20. Lima LM, de Souza LR, da Silva TF, Pereira CS, Guimaraes AL, de Paula AM, de Carvalho Andrade H (2012) DNA repair gene excision repair cross complementing-group 1 (ERCC1) in head and neck squamous cell carcinoma: analysis of methylation and polymorphism (G19007A), protein expression and association with epidemiological and clinicopathological factors. Histopathology 60:489–496PubMedCrossRefGoogle Scholar
  21. Mehra R, Cai KQ, Zhu F, Weaver J, Nicolaou N, Cohen RB, Lango M, Ridge JA, Godwin AK, Burtness B (2010) Analysis of ERCC1 (excision repair cross complementing group 1) in squamous cell carcinoma of the head and neck (SCCHN) by quantitative immunohistochemistry (IHC) using FL297. J Clin Oncol 28 (15s, Suppl):abstr. 5539Google Scholar
  22. Metzger R, Bollschweiler E, Hölscher AH, Warnecke-Eberz U (2010) ERCC1: impact in multimodality treatment of upper gastrointestinal cancer. Future Oncol 6:1735–1749PubMedCrossRefGoogle Scholar
  23. Murray D, Rosenberg E (1996) The importance of the ERC1/ERCC4 [XPF] complex for hypoxic-cell radioresistance does not appear to derive from its participation in the nucleotide excision repair pathway. Mutat Res 364:217–226PubMedCrossRefGoogle Scholar
  24. Niedernhofer LJ, Odijk H, Budzowska M, van Drunen E, Maas A, Theil AF, de Wit J, Jaspers NGJ, Berna Beverloo H, Hoeijmakers JHJ, Kanaar R (2004) The structure-specific endonuclease ERCC1-Xpf is required to resolve DNA interstrand cross-link-induced double-strand breaks. Mol Cell Biol 24:5776–5787PubMedCrossRefGoogle Scholar
  25. Nix P, Greenman J, Cawkwell L (2004) Expression of XRCC1 and ERCC1 proteins in radioresistant and radiosensitive laryngeal cancer. Cancer Ther 2:47–53Google Scholar
  26. Olaussen KA, Dunant A, Fouret P, Brambilla E, Andre F, Haddad V, Taranchon E, Filipits M, Pirker R, Popper HH, Stahel R, Sabatier L, Pignon JP, Tursz T, Le Chevalier T, Soria JC (2006) DNA repair by ERCC1 in non-small cell lung cancer and cisplatin based adjuvant chemotherapy. N Engl J Med 355:983–991PubMedCrossRefGoogle Scholar
  27. Reed E (1998) Platinum-DNA adduct, nucleotide excision repair and platinum based anti-cancer chemotherapy. Cancer Treat Rev 24:331–344PubMedCrossRefGoogle Scholar
  28. Romero Q, Bendahl P-O, Klintman M, Loman N, Ingvar C, Ryden L, Rose C, Grabau D, Borquist S (2011) Ki67 proliferation in core biopsies versus surgical samples—amodel for neo-adjuvant breast cancer studies. BMC Cancer. doi: 10.1186/1471-2407-11-341 PubMedGoogle Scholar
  29. Sargent RG, Meservy JL, Perkins BD, Kilburn AE, Intody Z, Adair GM, Nairn RS, Wilson JH (2000) Role of the nucleotide excision repair gene ERCC1 in formation of recombination dependent rearrangements in mammalian cells. Nucleic Acids Res 28:3771–3778PubMedCrossRefGoogle Scholar
  30. Scheil-Bertram S, Tylus-Schaaf P, du Bois A, Harter P, Oppitz M, Ewald-Riegler N, Fisseler-Eckhoff A (2010) Excision repair cross-complementation group 1 protein overexpression as a predictor of poor survival for high grade serous ovarian adenocarcinoma. Gynecol Oncol 119:325–331PubMedCrossRefGoogle Scholar
  31. Shirota Y, Stoehlmacher J, Brabender J, Xiang YP, Uetake H, Danenberg KD, Groshens S, Tsao-Wei DD, Danenberg P, Lenz HJ (2001) ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy. J Clin Oncol 19:4298–4304PubMedGoogle Scholar
  32. Simon GR, Sharma S, Cantor A, Smith P, Bepler G (2005) ERCC1 expression is a predictor of survival in resected patients with non-small cell lung cancer. Chest 127:978–983PubMedCrossRefGoogle Scholar
  33. Taillade L, Penault-Llorca F, Boulet T, Fouret P, Michiels S, Taranchon E, Mountzios G, Validire P, Domont J, Girard P, Grunenwald D, Le Chevalier T, Soria J-C (2007) Immunohistochemical expression of biomarkers: a comparative study between diagnostic bronchial biopsies and surgical specimens of non-small-cell lung cancer. Ann Oncol 18:1043–1050PubMedCrossRefGoogle Scholar
  34. Zamble DB, Mu D, Reardon JT, Sancar A, Lippard SJ (1996) Repair of cisplatin-DNA adducts by the mammalian excision nuclease. Biochemistry 35:10004–10013PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2012

Authors and Affiliations

  • Vesna Bišof
    • 1
    Email author
  • Antonija Jakovčević
    • 2
  • Sven Seiwerth
    • 2
  • Zoran Rakušić
    • 1
  • Slavko Gašparov
    • 3
  1. 1.Department of OncologyUniversity Hospital ZagrebZagrebCroatia
  2. 2.Department of Pathology and CytologyUniversity Hospital ZagrebZagrebCroatia
  3. 3.Department of Pathology and CytologyUniversity Hospital MerkurZagrebCroatia

Personalised recommendations